

## 2025

### **Improving genetic diagnosis of hereditary tumor syndromes: From expanded gene panels to functional genomics.**

Sauer M, Lucas MC, Prokosch V, Keßler T, Risch T, Laner A, Henkel J, Benet-Pagès A, Hallermayr A, Steinke-Lange V, Holinski-Feder E, Klink B.

<https://pubmed.ncbi.nlm.nih.gov/41347847/>

### **Fostering the implementation of liquid biopsy in clinical practice: meeting report 2024 of the European Liquid Biopsy Society (ELBS).**

Pantel K, Alix-Panabières C, Hofman P, Stoecklein NH, Lu YJ, Lianidou E, Giacomini P, Koch C, de Jager V, Deans ZC, Fairley J, Patton SJ, Toledo RA, Schuurung E, Heitzer E, Hendrix A, Ricklefs FL, Thakur BK, von Bubnoff N, Pierga JY, Gebhardt C, Andersen CL, Fijneman R, Malats N, Hallermayr A, Chelala C, Joosse SA, Ciliberto G.

<https://pubmed.ncbi.nlm.nih.gov/40410806/>

### **Reporting of molecular test results from cell-free DNA analyses: expert consensus recommendations from the 2023 European Liquid Biopsy Society ctDNA Workshop.**

de Jager VD, Giacomini P, Fairley JA, Toledo RA, Patton SJ, Joosse SA, Koch C, Deans ZC; ELBS ctDNA Workshop Group (Hallermayr A et al.), Pantel K, Heitzer E, Schuurung E.

<https://pubmed.ncbi.nlm.nih.gov/40121940/>

## 2024

### **Liquid Biopsy bei hereditärer Tumorprädisposition.**

Hallermayr A, Keßler T, König C, Steinke-Lange V, Holinski-Feder E.

coloproctology 46, 110–115 (2024). <https://doi.org/10.1007/s00053-024-00779-9>

### **Parallel in-depth analysis of repeat expansions: an updated Clin-CATS workflow for nanopore R10 flow cells.**

Scholz V, Schönrock V, Erdmann H, Prokosch V, Schoedel M, Almus M, Sauer M, Mayer V, Breithausen E, van Buren I, Dineiger C, Heintz C, Hallermayr A, Neuhann T, Holinski-Feder E, Abicht A, Benet-Pagès A, Lucas MC.

bioRxiv 2024.11.05.622099; doi: <https://doi.org/10.1101/2024.11.05.622099>

### **Whole genome methylation profiling to enhance diagnostic yield in neurodevelopmental disorders.**

Risch A, Auburger M, Kleinle S, Witzel M, Sadikovic B, Hallermayr A, Neuhann T, Abicht A.

Meeting abstracts of the clinical epigenetics international conference 2024. Clin Epigenet 16 (Suppl 1), 150 (2024).

<https://doi.org/10.1186/s13148-024-01749-0>

## 2023

### **Liquid Biopsy: minimal-invasive analysis of somatic alterations.**

Hallermayr A.

<https://pubmed.ncbi.nlm.nih.gov/38835738/>

### **The utility of liquid biopsy in clinical genetic diagnosis of cancer and monogenic mosaic disorders.**

Hallermayr A, Keßler T, Steinke-Lange V, Heitzer E, Holinski-Feder E, Speicher M.

<https://pubmed.ncbi.nlm.nih.gov/38835734/>

### **Reply: An epigenetic basis for genetic anticipation in facioscapulohumeral muscular dystrophy type 1.**

Erdmann H, Scharf F, Hallermayr A, Barseghyan H, Walter MC, Holinski-Feder E, Schoser B, Abicht A.

<https://pubmed.ncbi.nlm.nih.gov/37348868/>

### **Impact of cfDNA Reference Materials on Clinical Performance of Liquid Biopsy NGS Assays.**

Hallermayr A, Keßler T, Fujera M, Liesfeld B, Bernstein S, von Ameln S, Schanze D, Steinke-Lange V, Pickl JMA, Neuhann TM, Holinski-Feder E.

<https://pubmed.ncbi.nlm.nih.gov/37894392/>

## 2022

**Highly sensitive liquid biopsy Duplex sequencing complements tissue biopsy to enhance detection of clinically relevant genetic variants.**

Hallermayr A, Neuhann TM, Steinke-Lange V, Scharf F, Laner A, Ewald R, Liesfeld B, Holinski-Feder E, Pickl JMA.  
<https://pubmed.ncbi.nlm.nih.gov/36636551/>

**Somatic copy number alteration and fragmentation analysis in circulating tumor DNA for cancer screening and treatment monitoring in colorectal cancer patients.**

Ariane Hallermayr, Tobias Wohlfrom, Verena Steinke-Lange, Anna Benet-Pagès, Florentine Scharf, Ellen Heitzer, Ulrich Mansmann, Christopher Haberl, Maïke de Wit, Holger Vogelsang, Markus Rentsch, Elke Holinski-Feder, Julia M A Pickl  
<https://pubmed.ncbi.nlm.nih.gov/36056434/>

**Clinical Validity of Circulating Tumor DNA as Prognostic and Predictive Marker for Personalized Colorectal Cancer Patient Management**

Ariane Hallermayr, Verena Steinke-Lange, Holger Vogelsang, Markus Rentsch, Maïke de Wit, Christopher Haberl, Elke Holinski-Feder, Julia M A Pickl  
<https://doi.org/10.3390/cancers14030851>

## 2021

**Liquid Biopsy Hotspot Variant Assays: Analytical Validation for Application in Residual Disease Detection and Treatment Monitoring.**

Hallermayr A, Benet-Pagès A, Steinke-Lange V, Mansmann U, Rentsch M, Holinski-Feder E, Pickl JMA.  
<https://pubmed.ncbi.nlm.nih.gov/34392332/>

## 2018

**Imprinted and ancient gene: a potential mediator of cancer cell survival during tryptophan deprivation.**

Tomek P, Gore SK, Potts CL, Print CG, Black MA, Hallermayr A, Kilian M, Sattlegger E, Ching LM.  
<https://pubmed.ncbi.nlm.nih.gov/30466445/>

**Extending the critical regions for mutations in the non-coding gene RNU4ATAC in another patient with Roifman Syndrome.**

Hallermayr A, Graf J, Koehler U, Laner A, Schönfeld B, Benet-Pagès A, Holinski-Feder E.  
<https://pubmed.ncbi.nlm.nih.gov/30455926/>